Alogliptin benzoate (CAS 850649-62-6)

Application and positioning

Alogliptin benzoate is a selective DPP-4 inhibitor supplied as the benzoate salt. It is used in oral tablets for glycaemic control in type 2 diabetes, as monotherapy or with metformin. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Empagliflozin (CAS 864070-44-0)
• Ertugliflozin L-Pyroglutamic Acid (CAS 1210344-83-4)
• Linagliptin (CAS 668270-12-0)
• Sotagliflozin (CAS 1018899-04-1)
• 3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride (CAS 762240-92-6)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.